Aro Biotherapeutics Co announced it raised $24 Million in an initial filing from an offering of $100 Million

Company

Location

About

Unlocking the Potential of Genetic Medicines Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases.